MoonLake Immunotherapeutics
Ownership
Ownership Structure
Who owns MoonLake Immunotherapeutics (MLTX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 65.2% of the shares are freely tradable; institutional investors hold 79.0%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Bvf Inc | 18.80 | 16,001,284 | -19.0 | 03/31/2026 |
| Deep Track Capital, LP | 8.22 | 6,999,025 | +9.2 | 06/30/2026 |
| Cormorant Asset Management, LLC | 5.26 | 4,480,433 | +2.9 | 03/31/2026 |
| HHG PLC | 4.06 | 3,451,628 | +64.7 | 03/31/2026 |
| D. E. Shaw & Co LP | 3.95 | 3,365,507 | +40.8 | 06/30/2026 |
| Logos Global Management LP | 3.14 | 2,675,000 | +78.3 | 06/30/2026 |
| Citadel Advisors Llc | 2.32 | 1,972,893 | +49.0 | 06/30/2026 |
| Two Sigma Investments LLC | 2.02 | 1,715,349 | +52.8 | 06/30/2026 |
| Weiss Asset Management LP | 2.01 | 1,708,328 | +413.1 | 03/31/2026 |
| MPM Oncology Impact Management LP | 1.89 | 1,606,967 | -11.3 | 06/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.